# Elizabeth Iorns

> Elizabeth Iorns is a seed investor at Transcripta Bio (Palo Alto) backing Software and SaaS. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Transcripta Bio](https://shizune.co/investors/profile/transcripta-bio)
- Location: Palo Alto, United States
- Total investments: 6
- Last investment: Mar 2019
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/elizabethiorns
- X (Twitter): http://twitter.com/elizabethiorns
- Facebook: http://www.facebook.com/elizabeth.iorns

Elizabeth Iorns is a seed investor at Transcripta Bio in Palo Alto focused on Software and SaaS. Elizabeth Iorns is the Co-Founder, President, and CEO of Science Exchange. She previously worked at Y Combinator as a Part-time partner. Elizabeth Iorns attended the University of Auckland.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.9M–$3M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 3 | 50% |
| SaaS | 2 | 33% |
| Health Care | 2 | 33% |
| Health Diagnostics | 2 | 33% |
| Energy | 1 | 17% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 83% |
| Pre-Seed | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| Canada | 1 | 17% |
| Mexico | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Unima | Unima is decentralizing rapid testing across industries by taking diagnostics out of the lab to the place these are needed the most to secure a timely diagnostic for everyone, anywhere.Unima is solving is the centralization of lab testing, which limits the access to a timely diagnostic for billions. Current technology for diagnostics is veryprecise and can detect almost any disease known, but the problem is these require labs with expensive equipment and specialized technicians making lab testing impossible to scale up to provide universal and timely access to diagnostics.To solve this problem Unima developed Find, a rapid testing technology platform for real time diagnostics which allows anyone to diagnose a disease directly where it is needed, without using lab equipment, with results in 15 minutes or less and at a very low cost. With Find anyone can have access to a timely diagnostic even in the most remote areas of the world.The Find platform uses shark antibodies modified with genetic engineering to detect disease biomarkers in blood, saliva, urine or water samples. These shark antibodies are used in microfluidic cards and generate a visual reactions when in contact with specific biomarkers of the disease to be tested. Then to evaluate the result of the test, a picture of the testing card is taken with the proprietary Xplora smartphone app which runs image analysis process and neural network algorithms to generate an inmediate result. Then this result,along with contextual information like geolocation, date and time, is sent to a cloud server where it can be used for real time disease tracking. | $1.9M | Seed | Mar 24, 2019 |  |
| Enzyme | Enzyme is building software to help life sciences companies with FDA approval and regulatory compliance. Using Enzyme’s software, those companies can avoid spending money on costly consultants which in turn can reduce their compliance costs by up to 50 percent. Since 10 percent of all personnel in biopharma and life sciences companies are relatedto regulatory issues, it can lower headcount as well. Perhaps most importantly, Enzyme can also make it easier and faster for those companies to bring their products to market. | $1.9M | Seed | Oct 10, 2017 |  |
| Torch | Torch is a leadership development platform with integrated coaching, software, and feedback to raise high performers to the next level. It was founded by a team of executive coaches and experienced psychologists who are passionate about helping senior leaders perform at their highest level.Torch is on a mission to empower leaders to build highgrowth, high-performance cultures by building the awareness and skills required to manage and lead effectively.Our proven model blends human intelligence and digital technology to accelerate talent development and deliver measurable leadership outcomes. | $2.4M | Seed | Oct 04, 2017 |  |
| Validere | Validere is a measurement, reporting, and verification (MRV) SaaS company that helps energy organizations transform disconnected, incomplete emissions data into clear and immediately actionable pathways to financial and environmental value. Modernize your carbon tracking and reporting with an emissions management platform built by industry experts. | $2M | Seed | Sep 07, 2016 |  |
| Vetcove | Vetcove is like Kayak.com for veterinary hospitals to order their supplies. We aggregate the catalogs of all veterinary suppliers across the country, resulting in the largest veterinary catalog in the world, spanning more than 200,000 skus and 2,100 manufacturers. Clinics search one unified catalog with rich content, compare pricing and what'sin stock, and order in one place. Manufacturers, compounding pharmacies, and diagnostic laboratories manage their own product listings, receive payments, and offer free samples. For the first time ever, veterinarians and their staff can use collective insights to discover new products, buy smarter, and advance their practice of veterinary medicine. Our goal is to help vet hospitals operate profitably and assist them in providing the best possible products and services to pets and their pet parents. | $3M | Seed | Aug 22, 2016 |  |
| Vetcove | Vetcove is like Kayak.com for veterinary hospitals to order their supplies. We aggregate the catalogs of all veterinary suppliers across the country, resulting in the largest veterinary catalog in the world, spanning more than 200,000 skus and 2,100 manufacturers. Clinics search one unified catalog with rich content, compare pricing and what'sin stock, and order in one place. Manufacturers, compounding pharmacies, and diagnostic laboratories manage their own product listings, receive payments, and offer free samples. For the first time ever, veterinarians and their staff can use collective insights to discover new products, buy smarter, and advance their practice of veterinary medicine. Our goal is to help vet hospitals operate profitably and assist them in providing the best possible products and services to pets and their pet parents. | $3M | Pre-Seed | Aug 22, 2016 |  |

6 of 6 investments shown.

## Co-investors
- [Fuel Capital](https://shizune.co/investors/profile/fuel-capital) — VC Fund, 3 deals together
- [Y Combinator](https://shizune.co/investors/profile/y-combinator) — VC Fund, 3 deals together
- [Grape Arbor VC](https://shizune.co/investors/profile/grape-arbor-vc) — VC Fund, 2 deals together
- [Initialized Capital](https://shizune.co/investors/profile/initialized-capital) — VC Fund, 2 deals together
- [Avalancha Ventures](https://shizune.co/investors/profile/avalancha-ventures) — VC Fund, 1 deal together
- [Bodley Group](https://shizune.co/investors/profile/bodley-group) — VC Fund, 1 deal together

## About Transcripta Bio

VC Fund · Palo Alto, United States

Transcripta Bio is a company dedicated to drug discovery, with a focus on numerous diseases at once, at a never-before-seen pace and scale, with lesser risk and greater assurance.

2 contacts available at Transcripta Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Christopher Moxham | Founder, CEO and Chief Scientific Officer | https://shizune.co/investors/profile/christopher-moxham-0cda |
| Elizabeth Iorns | Scientific Founder & Advisor | https://shizune.co/investors/profile/elizabeth-iorns |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Energy Angel Investors in Canada](https://shizune.co/investors/energy-angel-investors-canada)
- [Sustainability Angel Investors in Canada](https://shizune.co/investors/sustainability-angel-investors-canada)
- [Impact Angel Investors in Canada](https://shizune.co/investors/impact-angel-investors-canada)
- [Oil and Gas Angel Investors](https://shizune.co/investors/oil-and-gas-angel-investors)
- [Biotechnology Angel Investors in LATAM](https://shizune.co/investors/biotechnology-angel-investors-latam)
- [Biotechnology Angel Investors in Mexico](https://shizune.co/investors/biotechnology-angel-investors-mexico)

## FAQ

### What does Elizabeth Iorns invest in?

Elizabeth Iorns invests primarily in Software, SaaS and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Elizabeth Iorns's check size?

Elizabeth Iorns typically joins rounds of $1.9M–$3M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Elizabeth Iorns participates in.

### When did Elizabeth Iorns last invest?

The most recent investment recorded for Elizabeth Iorns closed in Mar 2019. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co